Introduction {#sec1}
============

Multi-omics data integration approach is being preferred (as compared to be single omics) for addressing important biological questions^[@r1-2839775]^. While multi-omics methods have extensively been used for the subtype identification, these are naïve in the field of prognosis. State-of-the-art deep learning methods may be efficient in handling the multi-omics data for the development of efficient prognostic models. A plethora of bioinformatics studies used the deep learning algorithms to construct predictive models^[@r2-2839775]^. For instance, Cox-nnet is an artificial neural networks (ANN) based prognostic method that uses only single omics layer (transcriptomics)^[@r3-2839775]^. In contrast, DeepGene is a deep learning based method that classifies cancer types based on mutation profiles^[@r4-2839775]^. Deep learning algorithms present the advantage of handling high-dimensional data with numerous features and can exploit complex non-linear patterns, thanks to the activation functions. In particular, autoencoder is one of the DL algorithms which has gained popularity in recent times in biological domain. It has been used to find the unsupervised feature extraction in the breast cancer^[@r5-2839775]^.

Bladder cancer (BC) is the 9^th^ most commonly diagnosed cancer worldwide^[@r6-2839775]^. In the US alone, \~80K new incidences and \~17K deaths are estimated in 2017. BC is also amongst the few highly sex-disparate cancers where males have 4-folds higher risk (both incidence and death) than women^[@r7-2839775]^. According to an estimate, bladder cancer will be responsible for 7% of cancer diagnoses and 4% of cancer deaths from all the cancers in USA^[@r7-2839775]^. Smoking is considered as the major risk factor associated with the bladder cancer^[@r6-2839775]^. Furthermore, this cancer is more common in aged people (\>55 years). This disease is usually diagnosed at the later stage and the 5-year survival rate at advanced stage (IV) is around 15%^[@r8-2839775]^. Therefore, there is a pressing need for refining the diagnostic regimens to propose better risk-adapted therapies.

Two major subtypes are identified previously in bladder cancer-luminal and basal, where latter is more aggressive and characterized by *TP53* and *RB1* mutations. Further, two markers were found correlated with these two subtypes: *GATA3* for luminal and *KRT5/6* for basal^[@r9-2839775]^. Moreover, the study conducted by The Cancer Genome Atlas (TCGA), has identified four subtypes of urothelial bladder carcinoma based on the RNA-seq data^[@r10-2839775]^. In literature, a considerable work has been done to identify the survival related markers in BC from different individual omics layers. Studies show different genes, miRNA (miRs) and long non-coding RNAs (lncRNAs) for the survival prediction of bladder cancer^[@r11-2839775],\ [@r12-2839775]^. Though different studies identified several specific molecular subtypes of bladder cancer so far, but multi-omics integration along with utilization of survival information was not used while inferring the subtypes.

Here, we present a new extension of our original pipeline (namely DeepProg^[@r13-2839775]^), applied to the bladder cancer. DeepProg is a deep learning (autoencoder) based pipeline to infer the survival subgroups in unsupervised way followed by the prediction of survival subtype of the unknown sample. In the present work, we explored the use of autoencoder to transform multi-omics features followed by integration of survival information in order to identify subtypes linked with survival. To construct the model, we used the training dataset obtained from TCGA with three types of omics: mRNA, miRNA and methylation. For each omic, we constructed an individual autoencoder to produce new features linked to the survival. These features were then integrated together to infer the subtypes. We then developed a supervised classification model to identify the survival subtype of any new sample having common features with the training samples. This methodology has the advantages of being fast, robust and can be applied to various heterogeneous features potentially linked to survival. We anticipate that this pipeline will be a good starting point for data integration and survival-specific subtype identification.

Methods {#sec2}
=======

Dataset {#sec2-1}
-------

We obtained the three omics dataset i.e. mRNA, miRNA and methylation of TCGA BC from the Genomics Data Commons web portal (<https://portal.gdc.cancer.gov/>), as of June 2017. We used TCGA-Assembler, an open source pipeline for downloading, assembling and processing of 402 BC samples^[@r14-2839775]^. For mRNA sequencing data, we used normalized RSEM (RNA-Seq by Expectation Maximization) quantification values^[@r15-2839775]^ from the Illumina HiSeq platform. For miRNA sequencing quantification data, we procured the reads per million miRNA mapped (RPM) data from the Illumina HiSeq platform for each sample. For methylation (Infinium HumanMethylation450 BeadChip platform), the average methylation value of all the CpG sites was calculated for each gene within the 1500 bp ahead of the transcription start site (TSS). The corresponding survival data for these 402 samples were obtained from the FireBrowse (<http://firebrowse.org/>) website hosted by the Broad Institute.

For the validation dataset, we mined the Gene Expression Omnibus (GEO) database and found miRNA sequencing data for muscle-invasive bladder cancer for 62 samples along with survival information (GSE84525)^[@r16-2839775]^. We processed the raw read count data and converted those to the RPM, the same normalization as that of the TCGA miRNA dataset.

Model building {#sec2-2}
--------------

### Unsupervised inference of survival subtypes {#sec2-2-1}

We normalized each omic layer independently using the feature ranking and the per-sample correlation normalizations to produce three input matrices. Then, for each input matrix, we trained a denoising autoencoder to produce a new set of features specific to each omic. Finally, we searched for individual features linked to survival, stacked these features into a single matrix and clustered the samples ([Figure 1](#f1-2839775){ref-type="fig"}).

#### Normalization procedure {#sec2-2-1-1}

For each omic, we first normalized each sample independently using the rank normalization. For a given omic, we defined the input matrix *M = (v~1~,...,v~m~)* as the concatenation of *m* sample vectors *v*, having each *n* features. For a given sample vector *v = (x~1~,...,x~n~)*, the function *rank(x~i~)* returns the rank of the feature *x~i~* in *v* (1 if *x~1~* is the lowest value and *n* if it is the highest value). *v~rank~* is defined by: $$v_{rank} = \left( {rank\left( x_{1} \right),\ldots,\, rank\left( x_{n} \right)} \right).\frac{1}{n}$$

Then, we normalized *M~rank~ = (v~rank\ 1~,..., v~rank\ m~)* by computing the Pearson correlation distance between each pair of samples: $$M_{coor}\left( {i,j} \right) = d_{pearson}\left( {v_{rank\, i},v_{rank\, j}} \right)$$

Thus, *M~corr~ = {M~coor~(i,j)* \| *i,j Em}* is a square matrix of size *m*. Finally, for each sample vector of *M~corr~ = (m~1~,..., m~m~)*, we reapplied the rank normalization: $$M_{normalized} = \left( {m_{rank\, 1},\ldots,\, m_{rank\, m}} \right)$$

#### Autoencoder construction {#sec2-2-1-2}

For each input matrix, $M_{normalized}^{OMIC},$ we trained a denoising autoencoder using one hidden layer. An autoencoder can be defined as a function *f(v) = v'* where *v* is an input vector of size *n* and where *size(v') = size(v) = n. f* aims to reconstruct *v* using a combination of nonlinear transformations of its features. In the case of an autoencoder with one hidden layer with *h* nodes and with a same activation function for both encoder and decoder *f* is defined by: $$f\left( v \right) = \sigma\left( {W^{\prime}.\sigma\left( {W^{\prime}.v + b} \right) + b^{\prime}} \right)$$

With *W*, and *W'* represent the weight matrices with sizes *h × m and m × h*, and *b* and *b'* are two biases vectors of sizes *h* and *m*, respectively. Finally, *σ* is an element-wise non-linear activation function such as the *sigmoid* or the *relu* functions. The training procedure of an autoencoder uses an optimization algorithm such as the Stochastic Gradient Descent to find iteratively the best *W, W', b* and *b'* that minimize a loss function *loss(v, v ')*, measuring the difference between *v* and *v'.* We trained denoising autoencoder by setting a specific percentage of the weight matrices coefficients randomly to 0 (dropout) at each training iteration. This technique is known to reduce overfitting. Once the autoencoder is trained, the transformation *z* of *v* is given by *f(v) = σ(W.v+b).* We used the python Keras framework to create and train autoencoders. For each autoencoder, we used *h* = 100 (hidden nodes). We used the *logloss* as loss function, the *tanh* as activation function and the *adam* optimizer to minimize the loss. Finally, we trained the autoencoders on 50 epochs and with 50% of dropout rate. We denote *z^OMIC^* as the transformed version of $M_{normalized}^{OMIC}$ matrix

#### Identification of features linked to survival {#sec2-2-1-3}

We searched amongst the matrices produced by the autoencoder: *z^mRNA^, z^miRNA^* and *z^Methylatlon^*, the features linked to survival. For each feature of these matrices, we built a univariate Cox-PH model to identify and retained those with log-rank *pvalue \<* 0.01. We finally extracted these significant features and stacked them to form a new single matrix *Z\*.* We used the functions of the R *survival* package to build the Cox-PH model and compute the p-values.

#### Identification of the Survival subtypes {#sec2-2-1-4}

We used the Gaussian mixture algorithm to infer clusters from the matrix *Z\*.* We used the gaussian mixture library from the Python 2.7 scikit-learn package with 1000 iterations, 100 initiations and a diagonal covariance type (meaning that each cluster has its diagonal covariance matrix). The best number of clusters K was estimated by computing the Silhouette and the Calinski-Harabasz scores.

### Supervised inference of the survival subtype for a new sample {#sec2-2-2}

For each omic layer, we used the normalized matrices $M_{normalized}^{OMIC}$ and the labels inferred by the clustering procedure to build supervised classification models. We first selected from these matrices the individual top features to most correlated to the cluster labels to create a Support Vector Machine (SVM) model for each individual omic but also for the three-omics stacked together. To classify a new sample, we first normalized it using the rank normalization and then by computing the correlation distance with each sample of the training set. Finally, according to the omic type of the sample, we used the corresponding classifier to infer the survival subtype.

#### Classifiers construction {#sec2-2-2-1}

For each normalized matrix: $M_{normalized}^{mRNA},\, M_{normalized}^{miRNA}\text{ \ and\  }M_{normalized}^{mRNA},$ we used the Kruskal-Wallis test to select the top 10 features as the most discriminative according to the cluster labels. We then used these top features to construct an SVM model for each omic type. We also stacked the 30 features together to construct a "multi-omics" SVM model. Each SVM model was constructed using a grid-search procedure with a 5-fold cross-validation to find the best hyperparameters. As hyperparameter choices, we used two types of kernel: linear or Radial Basis Function (RBF) kernels. We also used an array of values for the penalty parameter C from 0.1 to 1000. We used the SVC and the model selection libraries from the scikit-learn package to construct the SVM models. In addition to the survival subtypes, we used the classifiers to infer the probability of a sample belonging to the subgroup with the lowest median survival ([Figure 2](#f2-2839775){ref-type="fig"}).

#### Normalization and classification of a new sample {#sec2-2-2-2}

A new sample can have features from one or multiple common omics with the training set. For each omic shared with the training samples, we selected the set of common features and applied the rank normalization on both, the new samples and the training set, using this subset of features. Then, we computed the Pearson correlation distance between the new sample and each sample of the training set. We used these values as new features which give a vector v. Finally, we applied again the rank normalization on v. Thus, the vector *v* and the matrices $M_{normalized}^{OMIC}$ have the same features. We then selected from *v* the 10 top features identified during the classification construction procedure and classified *v* using the corresponding classifier (for example, if *v* was derived from miR features only we used the miR classifier).

Model performance assessment {#sec2-3}
----------------------------

We split our dataset into training $\left( \frac{2}{3} \right)$ and test $\left( \frac{1}{3} \right)$ datasets. We then inferred the survival subtypes from the training set and built a classification model to infer the labels from the test set. We used the labels and label probabilities inferred for the test, training and the full datasets to fit Cox-PH models and used the log-rank p-values as performance criteria. Moreover, we reported the geometric mean of the p-values obtained for both the training and the test sets.

Validation {#sec2-4}
----------

### Survival {#sec2-4-1}

We used the *survival* package^[@r17-2839775]^ in R to analyze the survival difference between two subtypes in the main TCGA dataset and validation dataset. We used the *survdiff* function to compute the survival differences between two subtypes and plot the Kaplan-Meier curves with the log-rank P-values.

### Functional analysis post-hoc analysis {#sec2-4-2}

After getting the cluster labels for the main TCGA cohort for the two subtypes, we performed the *post-hoc* analysis to find out the differentially expressed features in the individual omic layers. We used the *edgeR* R package^[@r18-2839775]^ to perform the differential gene expression and filtered the upregulated and downregulated genes and miRs with a filter of log fold change \>2 and false discovery rate (FDR) \<0.05. For the differentially expressed genes, we mined the enriched pathways in the two subtypes using the *enrichr* tool^[@r19-2839775]^ and selected the final pathways satisfying the adjusted p-value \<0.05. For the differentially methylated genes, we first converted the beta values to the M-values using *lumi* R package^[@r20-2839775]^ and then used *limma* R package^[@r21-2839775]^ for the differential methylation gene identification using logFC \>1 and adjusted p-value \<0.05.

Results {#sec3}
=======

The inferred survival subtypes present significant and robust survival differences {#sec3-1}
----------------------------------------------------------------------------------

Using the silhouette score (top silhouette score: 0.39 for K=2) and the Calinski-Harabasz criterion, our model identified the optimal number of 2 subtypes amongst the BC population. Finally, on 20 successive and random splits of the TCGA 3-omics dataset in training (66%) and test (33%) sets, we obtained an overall p-value of 0.0008 and 0.04, using the cluster labels as predictor, for training and test set respectively ([Table 1](#t1-2839775){ref-type="table"}).

These results proved that the model used is robust towards the random process inherent to the autoencoder construction and the choice of the training sample. Moreover, the two subtypes in the full TCGA cohort presented a K-M estimates with clear segregation between the curves with log-rank p-value 1.8e-05 ([Figure 3A](#f3-2839775){ref-type="fig"}). Validation cohort also showed the significant differences with p-value=0.014 ([Figure 3B](#f3-2839775){ref-type="fig"}).

Specific molecular signatures are linked to bladder cancer survival subtypes {#sec3-2}
----------------------------------------------------------------------------

Differential gene expression analysis revealed 801 upregulated and 228 downregulated genes in the S1 cluster as compared to S2 subtype ([Figure 4A](#f4-2839775){ref-type="fig"}). We found *KRT6* and *KRT14* upregulated in the aggressive subtype (S1), which are in corroboration with the previous finding where these genes were reported to be the markers of basal (aggressive) subtype of bladder cancer^[@r9-2839775]^. Among the top upregulated genes in S1 subtype were *DLK1, TRH, DEFB103B, MYBPH* and *KRT38*, in contrast among top downregulated genes were *AMELX, MUC17, CYP1A2, SI* and *GC*.

18 upregulated and 10 downregulated miRs were identified in the differentially expressed miRs analysis in S1 as compared to S2 subtype ([Figure 4B](#f4-2839775){ref-type="fig"}). *mir-194* was found downregulated in S1 aggressive subtype down in bladder cancer and *miR-194* was reported to be acting as a tumor repressor and found downregulated in BC^[@r22-2839775]^. Upregulated *mir-133b* in S1 (aggressive) subtype was reported earlier to be associated with high risk and was also reported as a prognostic marker in progression free survival^[@r23-2839775]^.

For genes with differential methylation status, 918 hyper- and 46 hypo-methylated genes were obtained ([Figure 4C](#f4-2839775){ref-type="fig"}). Out of the hypermethylated genes, 6 were having mean difference greater than 2.5 and 2 hypomethylated genes were with mean difference \>1.5. *KRT13* was hypermethylated in S1 and it has been reported to be associated with high-grade disease in non-invasive bladder cancer^[@r24-2839775]^. *FHIT* and *LAMC2* which were found hypermethylated in S1 are also in corroboration with earlier work, where the methylated region in these two gene was reported to be associated with poor survival in patients ^[@r25-2839775]^.

Enriched pathway analysis revealed 31 activated pathways in S1 and 15 depleted pathways in S1 as compared to S2. Among the top activated pathways, cytokine-cytokine receptor interaction pathway (adj. p-value=1.97e-13), PI3K-Akt signaling pathway (adj. p-value=3.16e-06), and ECM-receptor interaction pathway (adj. p-value=5.13e-06) were enriched in S1 subtype ([Table 2](#t2-2839775){ref-type="table"}). PI3K-Akt signaling pathway was targeted earlier to inhibit the BC cell growth^[@r26-2839775]^. Cytokine-cytokine receptor interaction has been reported to be associated with BC progression^[@r27-2839775]^. Surprisingly, *Staphylococcus aureus* infection pathway has popped up as a top significant pathway. In the past this bacterium has shown the association with the schistosome infection which is known to be one of the risk factors in bladder cancer patients^[@r6-2839775]^. The association of parasites, bladder cancer and bacterium, may explain the significance of this pathway. In the enriched pathways for downregulated genes in S1, metabolism and drug and glucose metabolism apart from PPAR signaling pathways were present ([Table 2](#t2-2839775){ref-type="table"}).

mRNA transcriptomic features are the most informative features for survival prediction {#sec3-3}
--------------------------------------------------------------------------------------

We computed the importance of each omic layer to predict the survival subtype, by estimating the average number of new features linked to survival for each omic layer. RNA had the most important contribution with the average 14 features (out of 100) linked to survival followed by miRNA (6 features) and Methylation (2 features). Furthermore, this trend was reflected from the average p-value obtained with models using individual omic layer i.e. mRNA (0.001), miR (0.002) and methylation (0.004) with 20 iterations.

Discussion {#sec4}
==========

This is the cardinal study to use deep learning to integrate multi-omics data in order to find the survival risk stratification for bladder cancer samples. This new version of our DeepProg pipeline provides a flexible normalization procedure and a modularized architecture that can incorporate any new omic layer. Using samples from TCGA with 3-omics layers as the training set, we inferred two subtypes with significant and robust survival difference. Our pipeline achieved a significant stratification of the validation dataset, which contains only a single omic layer. Also, any new sample with a subset of features common with the training samples can be processed by DeepProg. The only preprocessing required is the distances computation between the new sample and the training samples. Thus, this strategy is more practical in the real-life situation where multi-omics for the external dataset are difficult to find. Finally, the modularity of the pipeline, i.e. an autoencoder is built for each omic layer, can be used to integrate any additional omic layer or survival related features, such as clinical image data^[@r28-2839775]^.

Several individual omic layer features are in agreement with the previously found markers including *KRT14* overexpression and enriched PI3K-Akt pathway in aggressive subtype. Thus, we postulate that our strategy can be useful in the future to create analytical pipelines with different degree of clinical interests. Furthermore, an improvement of the overall performance is attributable to the data quality (tumor purity) on which models are made in addition to the confounders *viz.* tumor heterogeneity, risk factors. It has been reported in a recent study that bladder cancer samples from TCGA belong to one of the least pure cancer type^[@r29-2839775]^, which makes survival analysis a challenging task. We anticipate that big cohort studies in the future with good quality of samples will be instrumental in improving the performance of our pipeline.
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###### 

Log-rank p-value of Cox-PH models for the training, test and validation datasets. The Cox-PH models were constructed using either the cluster label or the probability to belong the cluster with the lowest survival as single variable.

  Dataset                         p-value label      p-value label probability
  ------------------------------- ------------------ ---------------------------
  Training folds (20 iteration)   8e-4 (geo. mean)   7e-4 (geo. mean)
  Test folds (20 iteration)       0.04 (geo. mean)   0.03 (geo. mean)
  Final training dataset          0.002              0.001
  Final test dataset              0.03               0.02
  Validation dataset              0.02               0.02

###### 

Pathway enrichment analysis for the two subtypes.

  Pathway upregulated in SI                                Adjusted lvalue
  -------------------------------------------------------- -----------------
  Cytokine-cytokine receptor interaction                   1.97E-13
  Staphylococcus aureus infection                          3.91E-07
  PI3K-Akt signaling pathway                               3.16E-06
  Amoebiasis                                               3.77E-06
  Complement and coagulation cascades                      3.77E-06
  ECM-receptor interaction                                 5.13E-06
  Hematopoietic cell lineage                               6.61E-05
  Focal adhesion                                           1.94E-04
  Tuberculosis                                             2.47E-04
  Chemokine signaling pathway                              4.32E-04
  Rheumatoid arthritis                                     3.03E-04
  Jak-STAT signaling pathway                               1.Q8E-03
  Cell adhesion molecules (CAMs)                           9.81E-04
  Pertussis                                                7.78E-04
  Osteoclast differentiation                               3.84E-03
  Neuroactive ligand-receptor interaction                  4.43E-03
  Transcriptional misregulation in cancer                  4.43E-03
  Protein digestion and absorption                         3.77E-03
  Hypertrophic cardiomyopathy (HCM)                        5.41E-03
  Phagosome                                                5.41E-03
  Leishmaniasis                                            7.02E-03
  D i lated ca idiom yopat hy                              9.32E-03
  Malaria                                                  7.08E-03
  Toll-like receptor signaling pathway                     2.98E-02
  Systemic lupus erythematosus                             2.70E-02
  Calcium signaling pathway                                4.48E-02
  Arrhythmogenic right ventricular cardiomyopathy (ARVC)   2.53E-02
  Inflammatory bowel disease (IBD)                         3.56E-02
  Prion diseases                                           2.35E-02
  Graft-versus-host disease                                4.25 E-02
  Nicotinate and nicotinamide metabolism                   4.25E-02
  Metabolism of xenobiotics by cytochrome P450             2.37E-09
  Chemical carcinogenesis                                  1.15E-09
  Retinol metabolism                                       7.61E-09
  Drug metabolism - cytochrome P450                        1.12E-08
  Steroid hormone biosynthesis                             4.81E-07
  PPAR signaling pathway                                   2.97E-04
  Arachidonic acid metabolism                              1.40E-03
  Bile secretion                                           2.62E-03
  Starch and sucrose metabolism                            5.26E-03
  Ascorbateand aldarate metabolism                         3.45 E-03
  Metabolic pathways                                       1.74E-02
  Linoleic acid metabolism                                 4.12E-03
  Pentose and glucuronate inteiconversions                 8.01E-03
  Porphyrin and chlorophyll metabolism                     1.33E-02
  Drug metabolism - other enzymes                          1.74E-02
